The FSH pen injector is a medical device used for administering
follicle-stimulating hormone (FSH) injections. FSH is a hormone that
helps regulate the menstrual cycle and stimulates the development of
eggs in the ovaries. The pen injector is a convenient and easy-to-use
device that allows patients to self-administer FSH injections at home.
The pen injector contains a pre-filled cartridge of FSH medication and a
needle that is inserted into the skin to deliver the medication. The
device is designed to be simple, safe, and accurate, and it can be
adjusted to deliver the correct dosage of medication. The FSH pen
injector is commonly used in fertility treatments for women who are
trying to conceive. Fsh Pen Injector,Fertility Injection Pen,Hormone Pen Injectors,Disposable Hgh Pen Injector Shanghai Enjosim Medical Technology Co., Ltd , https://www.enjosimmedical.com
The first first-line treatment of new drugs in 10 years! Eisai Weima China listed
Pharmaceutical Network November 13th Japanese pharmaceutical company Eisai China subsidiary Eisai (China) Pharmaceutical Co., Ltd. recently announced the launch of the targeted anticancer drug Lenvima in the Chinese market (Chinese brand name: Le Wei Ma, General Name: Luvutinib mesylate). In March of this year, Eisai and Merck reached a global strategic cooperation to jointly develop and commercialize Lenvima. In the Chinese market, Eisai (China) will cooperate with Merck (China) to support Lenvima.
In China, Lenvima was approved in early September 2018 as a monotherapy for patients with unresectable hepatocellular carcinoma (HCC) who had not received systemic therapy. China is the country with the largest number of liver cancer patients in the world. The launch of Lenvima marks the first new systemic therapy for unresectable hepatocellular carcinoma (HCC) in China in the first 10 years.
Liver cancer is the second leading cause of cancer-related deaths, causing approximately 750,000 deaths worldwide each year, with 780,000 confirmed cases each year, of which about 80% occur in Asia, first China, followed by Africa. Specifically, in China, there are 395,000 new cases of liver cancer and 380,000 deaths each year, accounting for about 50% of global liver cancer cases.
Hepatocellular carcinoma (HCC) accounts for about 85%-90% of cases of primary liver cancer. Early stage HCC can be treated by a variety of means, including surgical resection, radiofrequency ablation, absolute ethanol injection, chemotherapy embolization, etc., but unresectable HCC is extremely refractory, treatment options are very limited, and the prognosis is extremely poor, resulting in There is a significant unmet medical need in this area. Previously, Bayer's targeted anticancer drug, Nexavar, was the only molecularly targeted drug approved for first-line treatment of unresectable HCC.
Lenvima's active pharmaceutical ingredient, lenvatinib, is an oral multi-receptor tyrosine kinase (RTK) inhibitor with novel binding patterns that are involved in inhibiting other pro-angiogenic and oncogenic signaling pathways involved in tumor proliferation. In addition to RTK, it is also capable of selectively inhibiting the kinase activity of the vascular endothelial growth factor (VEGF) receptor. Up to now, Lenvima has been approved by more than 50 countries including the United States, Japan, and the European Union for the treatment of refractory thyroid cancer, and more than 40 countries including the United States and the European Union have approved the combination of everolimus for the treatment of renal cell carcinoma ( RCC).
In March and August of this year, Lenvima was approved by Japan, the United States, and the European Union, becoming the first new first-line treatment for global advanced or unresectable HCC in the past 10 years.
The Chinese pharmaceutical market is the second largest market in the world after the United States. It was worth $122.2 billion in 2017 and is growing at a rate of 4%. The launch of Lenvima will further contribute to the health of liver cancer patients and their families in China.
Original Source: EISAI LAUNCHES LENVIMA® (LENVATINIB) IN CHINA